-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
The GMP inspection mainly focused on an innovative biological drug that WuXi Biologics provides commercial production services for its global partners.
Dr.
About WuXi Biologics
WuXi Biologics (stock code: 2269.
As of December 31, 2021, there were 480 comprehensive projects developed on the WuXi Biologics platform, including 268 in preclinical research, 171 in early clinical (Phase I/II), and 32 in late clinical (Phase I/II) Phase III) and 9 in the commercial production stage
WuXi Biologics regards Environmental, Social and Governance (ESG) as an important part of business development and entrepreneurship, and is committed to becoming a global ESG leader in biopharmaceuticals
For more information, please contact
Media Relations
Investor Relations